Tetanus Toxoid Vaccine Market Size & Share, Growth Analysis 2032

Tetanus Toxoid Vaccine Market Size - By Vaccine Type (Tetanus Toxoid (TT), Diphtheria and Tetanus (DT), Tetanus and Diphtheria (Td), Pentavalent, & Diphtheria, Tetanus, and Pertussis (DTaP)), Age Group (Pediatric, Adult), End-use & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increase in vaccines research and development in developed nations

3.2.1.2&nbsp;&nbsp;&nbsp;Growing cases of tetanus and diphtheria in some countries

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing government initiatives programs for vaccination

3.2.1.4&nbsp;&nbsp;&nbsp;Technological advancemen in development of toxoid vaccine

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Side-effects associated with toxoid vaccine

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Technological landscape

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.6.1&nbsp;&nbsp;&nbsp; Supplier power

3.6.2&nbsp;&nbsp;&nbsp; Buyer power

3.6.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.6.4&nbsp;&nbsp;&nbsp; Threat of substitutess

3.6.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.4&nbsp;&nbsp;&nbsp; Strategic outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Vaccine Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Tetanus toxoid (TT)

5.3&nbsp;&nbsp;&nbsp; Diphtheria and tetanus (DT)

5.4&nbsp;&nbsp;&nbsp; Tetanus and diphtheria (Td)

5.5&nbsp;&nbsp;&nbsp; Diphtheria, tetanus, and pertussis (DTaP)

5.6&nbsp;&nbsp;&nbsp; Tetanus, diphtheria, and pertussis (Tdap)

5.7&nbsp;&nbsp;&nbsp; Diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB)

5.8&nbsp;&nbsp;&nbsp; Pentavalent (DTaP-IPV/Hib)

5.9&nbsp;&nbsp;&nbsp; Hexavalent (DTaP-IPV/Hib-HepB)

5.10&nbsp;&nbsp;&nbsp; Other vaccine types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Pediatric

6.3&nbsp;&nbsp;&nbsp; Adult

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-Use, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospitals and clinics

7.3&nbsp;&nbsp;&nbsp; Government organizations

7.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Italy

8.3.5&nbsp;&nbsp;&nbsp; Spain

8.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Bharat Biotech International Limited

9.2&nbsp;&nbsp;&nbsp; Biological E. Limited

9.3&nbsp;&nbsp;&nbsp; Biological Products Institute (BPI) Argentina

9.4&nbsp;&nbsp;&nbsp; Chengdu Institute of Biological Products Co., Ltd.

9.5&nbsp;&nbsp;&nbsp; GlaxoSmithKline

9.6&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

9.7&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

9.8&nbsp;&nbsp;&nbsp; Mitsubishi Tanabe Pharma Corporation

9.9&nbsp;&nbsp;&nbsp; Panacea Biotec Limited

9.10&nbsp;&nbsp;&nbsp; Pfizer Inc.

9.11&nbsp;&nbsp;&nbsp; Sanofi

9.12&nbsp;&nbsp;&nbsp; Serum Institute of India

9.13&nbsp;&nbsp;&nbsp; Zydus Group 
&nbsp;

Tetanus Toxoid Vaccine Market

Get a free sample of this report